Ann: Emyria Completes Acquisition of the Pax Centre, page-7

Obs the correct answer is EMD.

I find the two companies, EMD and IHL, to be distinct in several positive ways that make EMD an attractive investment choice:

• EMD places a significant emphasis on the clinical and development side of its operations, which sets it apart from IHL. Unlike IHL, where the focus seems to be more on exchange dynamics
• IHL has a big retail pump so be wary of "narrative economics"
• EMD's management has a wealth of experience in the pharmaceutical industry. For instance, our CEO has worked directly with Palentair & the FDA on their Real-World Data (RWD) frameworks and clinical models, providing invaluable expertise. In contrast, IHL's CEO lacks a pharmaceutical background, which could be a potential drawback for investors.
• EMD's CEO, with a strong background in RWD and FDA collaborations, is compensated at a more reasonable rate of 0.5 million, which is 33% less than IHL's CEO at 1.5 million, who lacks pharmaceutical experience. This highlights EMD's commitment to responsible and efficient corporate governance.
• EMD boasts a tightly held register, with a substantial portion owned by the top 20 and management. This indicates a high level of confidence and commitment among key stakeholders.
• In terms of clinical services (outside of the ones we already have), EMD has made a strategic acquisition of the Pax Center, a well-established entity with a substantial revenue stream, a loyal customer base, and a team of ~15 clinical psychologists. In contrast, IHL's recent venture into a new psychology clinic appears to lack the same level of customer engagement and experience. (no customers / who is the psychologist)
• When considering the success stories in the industry, such as Jazz's acquisition for 7 billion, it becomes clear that companies like EMD have a careful eye of big pharma so much so that they joined the board.
• EMDs RWD framework compounds on itself, which means that our drug development pipeline can "speed" through steps, it also means that certain trials can have a lower cost due to the additional RWD that can be provided.
• the clinics provide a great revenue stream - 14,000 people whose data that we "add" to the body of evidence.
• EMD we see management buying
• IHl we do not see management buying - even at these lows